- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05698043
A Clinical Trial to Evaluate the Tolerability and Pharmacokinetics of CKD-386(5) 80/20/10mg
October 29, 2023 updated by: Chong Kun Dang Pharmaceutical
An Open Label, Randomized, Single Dose, 2-sequence, 4-period, Cross-over Clinical Trial to Evaluate the Pharmacokinetics and the Tolerability of CKD-386(5) With Co-administration of D013, D326, and D337 in Healthy Adult Volunteers
A Clinical Trial to evaluate the Pharmacokinetics and Tolerability of CKD-386(5)
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
An open label, randomized, single dose, 2-sequence, 4-period, cross-over clinical trial to evaluate the pharmacokinetics and the tolerability of CKD-386(5) with co-administration of D013, D326, and D337 in healthy adult volunteers
Study Type
Interventional
Enrollment (Actual)
63
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Jaewoo Kim, M.D.
- Phone Number: +82-70-4665-9193
- Email: m3116@newyjh.com
Study Locations
-
-
-
Seoul, Korea, Republic of
- H plus Yangji Hospital
-
Contact:
- Jaewoo Kim, M.D.
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
19 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
Yes
Description
Inclusion Criteria:
- Healthy adult volunteers aged ≥ 19 years
- Weight ≥55kg with calculated body mass index (BMI) of 18 to 30 kg/m2
Those who meet the blood pressure criteria during screening tests:
- Systolic Blood Pressure: 90 to 139 mmHg
- Diastolic Blood Pressure: 60 to 89 mmHg
- Those who have no congenital diseases or chronic diseases and have no abnormal symptoms or findings.
- Those who are eligible for clinical trials based on laboratory(hematology, blood chemistry, serology, urology) and 12-lead ECG results at screening.
- Those who agree to contraception during the participation of clinical trial.
- Individuals who voluntarily decide to participate and agree to comply with the cautions after fully understand the detailed description of this clinical trial.
Exclusion Criteria:
- Those who received investigational products or participated in bioequivalence tests within 6 months before the first administration of clinical trial drugs.
- Those who have used drugs that induce or inhibit drug metabolizing enzymes, such as barbiturates, within 1 month before the first dosing date, or who have used drugs that may interfere with this study within 10 days before the first dosing day (However, clinical investigational drugs) Participation is possible in consideration of pharmacokinetic and pharmacodynamic characteristics such as interaction with concomitant drugs and half-life of concomitant drugs)
- Those who donated whole blood or apheresis within 8 weeks or 4 weeks respectfully, or received blood transfusion within a 4 weeks.
- Those who have a history of gastrointestinal surgery except simple appendectomy and hernia surgery.
Those who exceed an alcohol and cigarette consumption than below criteria
- Alcohol: Man_21 glasses/week, Woman_14 glasses/week (1 glass: Soju 50mL, Wine 30mL, or beer 250mL)
- Heavy Smoking: 20 cigarettes/day
Patients with the following diseases
- Patients with hypersensitivity to the main constituents or components of the investigational drug
- Severe hepatic impairment, biliary atresia or cholestasis
- Patients with hereditary angioedema or with a history of angioedema in the treatment of ACE inhibitors or angiotensin II receptor antagonists
- Diabetes mellitus
- Patients with moderate to severe renal impairment [glomerular filtration rate (eGFR) <60 mL / min / 1.73m^2]
- Renal vascular hypertension patients
- Patients with active liver disease, including unexplained persistent serum transaminase elevations or elevated serum transaminase elevations greater than three times the normal upper limit
- Patients with myopathy or have a history of family or genetic history of myopathy
- Hypothyroidism
- If you have a history of muscle toxicity for other HMG-CoA converting enzymes or fibrate class drugs
- Those who have genetic problems such as galactose intolerance, Lapp lactose deficiency or glucose-galactose malabsorption.
- Those who are deemed insufficient to participate in this clinical study by investigators.
- Woman who are pregnant or breastfeeding.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Sequence 1
|
Test
Reference
|
Experimental: Sequence 2
|
Test
Reference
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
AUCt of CKD-386(5)
Time Frame: Pre-dose (0 hour), 0.25, 0.5, 0.75, 1, 1.25, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72 hours
|
Area under the concentration-time curve from time zero to time
|
Pre-dose (0 hour), 0.25, 0.5, 0.75, 1, 1.25, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72 hours
|
Cmax of CKD-386(5)
Time Frame: Pre-dose (0 hour), 0.25, 0.5, 0.75, 1, 1.25, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72 hours
|
Maximum plasma concentration of the drug
|
Pre-dose (0 hour), 0.25, 0.5, 0.75, 1, 1.25, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72 hours
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Jaewoo Jaewoo, M.D., H plus Yangji Hospital
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
July 17, 2023
Primary Completion (Actual)
September 1, 2023
Study Completion (Actual)
September 26, 2023
Study Registration Dates
First Submitted
January 16, 2023
First Submitted That Met QC Criteria
January 16, 2023
First Posted (Actual)
January 26, 2023
Study Record Updates
Last Update Posted (Actual)
November 1, 2023
Last Update Submitted That Met QC Criteria
October 29, 2023
Last Verified
October 1, 2023
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- A83_10BE2223
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Hypertension and Dyslipidemia
-
Boryung Pharmaceutical Co., LtdCompleted
-
Boryung Pharmaceutical Co., LtdCompletedEssential Hypertension, DyslipidemiaKorea, Republic of
-
Daewoong Pharmaceutical Co. LTD.UnknownHypertension, DyslipidemiaKorea, Republic of
-
Boryung Pharmaceutical Co., LtdCompletedHypertension and DyslipidemiaKorea, Republic of
-
Jeil Pharmaceutical Co., Ltd.CompletedDyslipidemia With HypertensionKorea, Republic of
-
Chong Kun Dang PharmaceuticalCompletedDyslipidemia Patients With HypertensionKorea, Republic of
-
IlDong Pharmaceutical Co LtdNot yet recruitingHypertension, Dyslipidemia
-
Chong Kun Dang PharmaceuticalCompletedHypertension and DyslipidemiaKorea, Republic of
-
Daewon Pharmaceutical Co., Ltd.Completed
-
Chong Kun Dang PharmaceuticalCompletedHypertension and DyslipidemiaKorea, Republic of
Clinical Trials on CKD-386(5)
-
Chong Kun Dang PharmaceuticalUnknownHypertension | DyslipidemiasKorea, Republic of
-
Chong Kun Dang PharmaceuticalUnknown
-
Chong Kun Dang PharmaceuticalCompletedHypertension | DyslipidemiasKorea, Republic of
-
Chong Kun Dang PharmaceuticalCompletedHypertension and DyslipidemiaKorea, Republic of
-
Chong Kun Dang PharmaceuticalCompletedHypertension and DyslipidemiaKorea, Republic of
-
Chong Kun Dang PharmaceuticalCompletedHypertension and DyslipidemiaKorea, Republic of
-
Chong Kun Dang PharmaceuticalCompletedHypertension and DyslipidemiaKorea, Republic of
-
Chong Kun Dang PharmaceuticalCompletedHypertension and DyslipidemiaKorea, Republic of
-
Chong Kun Dang PharmaceuticalCompletedHypertension and DyslipidemiaKorea, Republic of
-
Cardiff UniversityPodiatry Department, Cardiff & Vale University Health Board; School of Health... and other collaboratorsUnknownChronic Kidney DiseaseUnited Kingdom